Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Shares of Tempus AI (TEM) are rising 5% in pre-market trading after surging 13% yesterday. The healthcare-focused AI stock ...

Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Thursday after the company announced a collaboration with the ...

Tempus AI (TEM) announced a new collaboration with the Institute for Follicular Lymphoma Innovation. The collaboration aims to develop and make ...

Tempus AI (TEM) stock surged 13.4% on Thursday, hitting a new 52-week high of $86. The upside came after the health ...

Tempus AI shares soared to an all-time high Thursday as the tech firm announced a collaboration with the nonprofit Institute ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...